Weight Watchers (WW) Q1 2026 earnings review
Clinical Subs Rebound Dramatically, But Legacy Anchor Drags Down Total Revenue
Weight Watchers delivered a highly polarized Q1. The clinical segment completely absorbed the shock of losing its compounded semaglutide offering last year, engineering a reversing trend with a 51% sequential surge in subscribers. However, this clinical success was entirely overshadowed by the continued freefall in the legacy Behavioral business, which shed over 800,000 subscribers year-over-year. Despite record-high adjusted gross margins (73.6%) and an impressive 13% climb in ARPU driven by the clinical mix shift, heavy peak-season marketing spend pushed Adjusted EBITDA into negative territory (-$1.8M). Management's FY26 guidance indicates another year of top-line contraction, confirming the turnaround remains a grueling, multi-year process.
🐂 Bull Case
Clinical subscribers grew 46% YoY and 51% sequentially to 197,000, proving the company can attract users to its FDA-approved GLP-1 companion programs even after ceasing the sale of cheaper compounded alternatives.
Total ARPU expanded 13% YoY to $20.59. This is driven by a massive mix shift: Clinical ARPU ($79.23) is over 4x higher than Behavioral, and the higher-tier 'Core+' behavioral program returned to growth (+6% YoY).
🐻 Bear Case
Behavioral subscribers fell 25.4% YoY, accelerating the total revenue decline to 10% YoY. The core business is bleeding members faster than the clinical business can replace them.
To achieve the clinical subscriber bump, WW had to spend heavily on marketing during peak season ($93M), which completely wiped out operating profit and drove Adjusted EBITDA to a $1.8M loss.
⚖️ Verdict: ⚪
Neutral. The underlying mechanics of the transition are finally showing positive proof points (ARPU, Clinical subs, Gross Margins), but the relentless top-line decay and guidance for further revenue contraction in FY26 demand patience that many investors may not have.
Key Themes
Clinical Segment Accelerating Past Compounding Headwinds
The most important takeaway from Q1 is that the Clinical segment is reversing its prior stagnation. After shedding members in mid-2025 due to the forced end of compounded semaglutide prescriptions, Clinical subscribers skyrocketed 51% sequentially. This was catalyzed by expanded access to Novo Nordisk's Wegovy and Ozempic Pills and Eli Lilly's oral GLP-1, demonstrating WW's ability to navigate the complex FDA-approved medication landscape.
Mix-Shift Powering ARPU Expansion
A massive mix shift is creating stable ARPU growth. Total ARPU grew 13% YoY to $20.59. Not only did Clinical revenue grow 32% YoY (carrying an ARPU of $79.23), but within the Behavioral segment, the higher-tier 'Core+' offering grew 6% to 537,000 subscribers. Core+ ARPU is nearly double that of the basic tier, successfully offsetting some of the volume losses in the legacy business.
Operational Efficiencies Protect Margins
Despite a lower revenue base, Adjusted Gross Margin remained stable at 73.6%, near record highs. Management's structural cost actions, including previous headquarters downsizing and workflow automation, have established a highly variable cost structure that protects unit economics even as total volume declines.
Core Behavioral Segment Decelerating Severely
The legacy Behavioral business continues to act as a massive drag on the entire enterprise. Behavioral Subscription Revenue collapsed 17.5% YoY to $128.5M, driven by a 25.4% drop in End of Period Behavioral Subscribers (from 3.3M to 2.46M). Until this decline bottoms out, WW cannot return to enterprise-wide top-line growth.
Marketing Spend Wiping Out Profitability
The narrative of 'profitable clinical growth' is directly contradicted by the bottom line. Marketing expenses surged to $92.9M (55.2% of total revenue), driving a steep operating loss and an Adjusted EBITDA loss of $1.8M. WW is paying a heavy premium to acquire these new Clinical members, raising questions about customer acquisition costs (CAC) and lifetime value (LTV) in a post-compounding era.
Fresh Start Accounting Obscuring GAAP Earnings
Following the mid-2025 reorganization, Fresh Start Accounting resulted in significantly higher depreciation and amortization ($25.9M in Q1 26 vs $6.9M in Q1 25). This heavily distorted GAAP EPS to an alarming -$5.20 on a much smaller share count (10M shares). While non-cash, it creates a messy optical picture for retail investors trying to value the new equity.
Macro: GLP-1 Landscape Shifting to Oral Medications
Management highlighted that the GLP-1 market is rapidly evolving with the launch of oral formulations. WW is integrating with Eli Lilly's LillyDirect and Novo Nordisk's NovoCare to distribute these pills. This macro shift is vital for WW, as oral medications lower the barrier to entry (needle aversion) and generally carry lower price points, broadening the total addressable market.
Other KPIs
Reversing to a sharp cash burn compared to the +$15.0M generated in the prior year period. This was primarily driven by front-loaded peak-season marketing payments. The company expects to return to positive cash generation in the remaining quarters of the year.
The company's balance sheet remains the primary beneficiary of the 2025 reorganization. In Q2 2026, WW plans to use $37M of its $121M cash pile to prepay $42M of its term loan (utilizing a discounted voluntary solicitation). This aggressive deleveraging will save an additional $4M in annualized interest expense.
Guidance
Decelerating. The midpoint of $627.5M implies a ~10% YoY decline compared to the ~$697M generated in FY25. This confirms that the severe behavioral subscriber losses will continue to outweigh the rapid growth of the much smaller clinical base for at least another 12 months.
Decelerating. Down from the $145M-$150M range targeted in late FY25. Despite maintaining ~72%+ gross margins, top-line contraction and sustained investments in marketing and product development are squeezing absolute EBITDA dollars.
Accelerating dramatically. Clinical revenue is expected to jump to roughly 25-30% of total revenue in FY26, up from just 16% in FY25. This fundamental shift completely alters the company's unit economics and risk profile.
Key Questions
Clinical CAC and LTV Economics
With marketing expense at 55% of revenue in Q1 to drive the 51% sequential bump in Clinical subs, what is the exact Customer Acquisition Cost for a Clinical member versus a Behavioral member? How long is the payback period?
Behavioral Trough
You are guiding for FY26 revenue to contract again. What is the internal projection for when the Behavioral subscriber count finally reaches a floor and stops bleeding?
Oral GLP-1 Pricing Impact
As oral GLP-1 formulations become widely available, how do you expect this to impact clinical gross margins and medication adherence retention rates compared to injectables?